Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms Flotegatide F18, RGD F18, RGD-F18 |
Target |
Action stimulants |
Mechanism αvβ3 stimulants(Integrin alpha-V/beta-3 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC41H60FN13O13 |
InChIKeySDQRGILXNZSUMD-ABRGNQFASA-N |
CAS Registry1010702-75-6 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Head and Neck Carcinoma | Phase 2 | France | 20 Mar 2015 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | France | 20 Mar 2015 | |
| Carotid Stenosis | Phase 2 | United States | 01 May 2012 | |
| Breast Cancer | Phase 2 | United States | 01 Sep 2009 | |
| Colorectal Cancer | Phase 2 | United States | 01 Sep 2009 | |
| Non-Small Cell Lung Cancer | Phase 2 | United States | 01 Sep 2009 | |
| Glioma | Phase 1 | United States | 01 Aug 2008 | |
| Melanoma | Phase 1 | United States | 01 Aug 2008 | |
| Sarcoma | Phase 1 | United States | 01 Aug 2008 | |
| Atherosclerosis | Preclinical | United States | - |





